COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk

will begin a new trial to explore further weight-loss potential

of its experimental CagriSema drug in the first half of 2025,

the company said on Friday, after posting disappointing data for

the drug candidate.

"We plan to optimize dose titration to further explore

CagriSema's additional weight loss potential with a new trial

planned to start in the first half of 2025," a spokesperson said

in an email to Reuters.

Earlier on Friday, Novo said CagriSema helped patients cut

their weight by 22.7% in a late-stage trial, below the 25% it

had expected, wiping as much as $125 billion off its market

value.